ORI-INDUSTRIES
4.10.2021 07:02:05 CEST | Business Wire | Press release
London based edge computing pioneer Ori Industries is partnering with VMware, Inc. (NYSE: VMW), a leading innovator in enterprise software, to facilitate enterprise implementation of edge computing across hybrid, telco and multi-cloud deployments. The interoperability of VMware Telco Cloud Platform and Ori Global Edge reduces complexity, increases service velocity, and manageability of cloud-native service delivery at the edge.
According to Gartner 1 , “edge computing is entering the mainstream”; however, many enterprises struggle with their existing cloud deployments proving to be a barrier to edge adoption. Ori and VMware’s partnership will help overcome this challenge by offering a fully functioning edge platform that connects to any cloud environment from telco to hybrid to multi-cloud.
Ori Global Edge on VMware Telco Cloud Platform is a managed cloud service offering that delivers a multi-connected edge by using multiple points of presence (PoP) that connect to the telco and communications service provider (CSP) infrastructure on one end and different clouds on the other end. The solution2 enables CSPs to offer multi-access edge computing (MEC) capabilities, which allow them to greater monetize their 5G offering to the enterprise. At the same time, it allows them to reduce their backhaul costs through intelligent workload placement.
Customers will benefit from service availability at the edge with low latency, highly-available applications generating and processing data locally without overhead for data transfer back to the cloud for processing. Extracting, analysing and using data at the edge permits a new class of enterprise services for enhanced customer experience.
Stephen Spellicy , vice president of product marketing, Service Provider and Edge, VMware, said, “Enterprises are looking for new ways to engage customers and deliver next-generation experiences. That means having the right application deployed where the user is. Edge computing is the final piece of the puzzle and working with Ori Industries’ multi-access edge computing platform will give mutual customers the ability to deploy a solution that helps cover all their environments – whether telco, hybrid, multi-cloud or edge – to meet their business needs.”
Douglas Mancini , CCO at Ori Industries said “Edge computing offers enterprises immense opportunities to not only deliver new innovative solutions but also reinvent their existing infrastructure in a more efficient way: Enterprises have learned that a pure cloud-first model has failed to deliver the expected value or agility, and Ori Global Edge is helping do just that. By combining our edge computing expertise with VMware Telco Cloud Platform and multi-cloud leadership, we are able to offer enterprises a way of harnessing the power of edge and reaping the benefits of being able to use data near to its creation.”3
For more information visit: https://ori.co/ .
About Ori Industries
Ori Industries is laying the foundation for the global rollout of edge computing services. The company’s edge platform simplifies workload provisioning across public, Telco, hybrid, and multi-cloud infrastructure to support countless new and emerging enterprise use cases. Ori Industries is based in London with a global workforce. For more information, please visit https://www.ori.co/ .
VMware and VMware Telco Cloud Platform are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.
1
https://www.gartner.com/en/documents/3992656/2021-strategic-roadmap-for-edge-computing
2
Solution Overview: https://www.vmware.com/content/dam/digitalmarketing/vmware/en/pdf/microsites/telco/vmware-ori-solution-brief.pdf
3
Video Interview: https://www.youtube.com/watch?v=R-fUFNElWzo
View source version on businesswire.com: https://www.businesswire.com/news/home/20211003005023/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom